Mylotarg Approved for AML: Drug Returns to Market Mylotarg Approved for AML: Drug Returns to Market
After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Health | Hematology | Leukemia